Evaluation of the FTA carrier device for human papillomavirus testing in developing countries

Journal of Clinical Microbiology

Volumn 50, Issue 12, 2012, Pages 3870-3876

  Gonzalez, Paula ^a,b   Cortes, Bernal ^a   Quint, Wim ^d   Kreimer, Aimée R ^c   Porras, Carolina ^a   Rodríguez, Ana Cecilia ^a   Jimenez, Silvia ^a   Herrero, Rolando ^b   Struijk, Linda ^d   Hildesheim, Allan ^c   Melchers, Willem ^e  

^a PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c NATIONAL CANCER INSTITUTE   (United States)

^d DDL DIAGNOSTIC LABORATORY   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CONTROLLED STUDY; DEVELOPING COUNTRY; DNA DETERMINATION; DNA ISOLATION; ENZYME IMMUNOASSAY; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INTERMETHOD COMPARISON; LABORATORY DEVICE; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR VIRUS; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS TYPING; WART VIRUS;

ADULT; CLINICAL LABORATORY TECHNIQUES; COSTA RICA; DEVELOPING COUNTRIES; DNA, VIRAL; EQUIPMENT AND SUPPLIES; FEMALE; GENOTYPE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; VIROLOGY; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS;

EID: 84869223450     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01698-12     Document Type: Article

References (31)

1. Arbyn M, et al. 2006. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24(Suppl 3):78-89.
2. Bellini WJ, Helfand RF. 2003. The challenges and strategies for laboratory diagnosis of measles in an international setting. J. Infect. Dis. 187(Suppl 1):S283-S290. (Pubitemid 36583968)
3. Bertagnolio S, Parkin NT, Jordan M, Brooks J, Garcia-Lerma JG. 2010. Dried blood spots for HIV-1 drug resistance and viral load testing: a review of current knowledge and WHO efforts for global HIV drug resistance surveillance. AIDS Rev. 12:195-208.
4. Condorelli F, et al. 1998. Use of a microquantity enzyme immunoassay in a large-scale study of measles, mumps and rubella immunity in Italy. Eur. J. Clin. Microbiol. Infect. Dis. 17:49-52. (Pubitemid 28072291)
5. de Bie RP, et al. 2011. The indicating FTA elute cartridge a solid sample carrier to detect high-risk HPV and high-grade cervical lesions. J. Mol. Diagn. 13:371-376.
6. De Swart RL, et al. 2001. Combination of reverse transcriptase PCR analysis and immunoglobulin M detection on filter paper blood samples allows diagnostic and epidemiological studies of measles. J. Clin. Microbiol. 39:270-273. (Pubitemid 32059602)
7. Franco E, et al. 1999. Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Ludwig-McGill Study Group. Rev. Panam. Salud Publica 6:223-233. (Pubitemid 29523611)
8. Gupta BP, Jayasuryan N, Jameel S. 1992. Direct detection of hepatitis B virus from dried blood spots by polymerase chain reaction amplification. J. Clin. Microbiol. 30:1913-1916.
9. Gustavsson I, Lindell M, Wilander E, Strand A, Gyllensten U. 2009. Use of FTA card for dry collection, transportation and storage of cervical cell specimen to detect high-risk HPV. J. Clin. Virol. 46:112-116.
10. Gustavsson I, et al. 2011. Type-specific detection of high-risk human papillomavirus (HPV) in self-sampled cervicovaginal cells applied to FTA elute cartridge. J. Clin. Virol. 51:255-258.
11. He H, Argiro L, Dessein H, Chevillard C. 2007. Improved technique that allows the performance of large-scale SNP genotyping on DNA immobilized by FTA technology. Infect. Genet. Evol. 7:128-132. (Pubitemid 44882894)
12. Herrero R, et al. 2008. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 26:4795-4808.
13. Herrero R, et al. 1997. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev. Panam. Salud Publica 1:362-375. (Pubitemid 27428425)
14. IARC. 1995. IARC monograph on the evaluation of carcinogenic risks to humans, vol 64. Human papillomaviruses. IARC, Lyon, France.
15. Katki HA, et al. 2011. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 12:663-672.
16. Kerr RJ, Player G, Fiscus SA, Nelson JA. 2009. Qualitative human immunodeficiency virus RNA analysis of dried blood spots for diagnosis of infections in infants. J. Clin. Microbiol. 47:220-222.
17. Kleter B, et al. 1999. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J. Clin. Microbiol. 37:2508-2517. (Pubitemid 29337270)
18. Kleter B, et al. 1998. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am. J. Pathol. 153:1731-1739. (Pubitemid 28550661)
19. Kraus RH, et al. 2011. Avian influenza surveillance with FTA cards: field methods, biosafety, and transportation issues solved. J. Vis. Exp. e2832.
20. Lenselink CH, et al. 2009. Detection and genotyping of human papillomavirus in self-obtained cervicovaginal samples by using the FTA cartridge: new possibilities for cervical cancer screening. J. Clin. Microbiol. 47:2564-2570.
21. Michaud V, et al. 2007. Long-term storage at tropical temperature of dried-blood filter papers for detection and genotyping of RNA and DNA viruses by direct PCR. J. Virol. Methods 146:257-265. (Pubitemid 350030944)
22. Milne E, et al. 2006. Buccal DNA collection: comparison of buccal swabs with FTA cards. Cancer Epidemiol. Biomarkers Prev. 15:816-819.
23. Muoz N, Castellsague X, de Gonzalez AB, Gissmann L. 2006. Chapter 1: HPV in the etiology of human cancer. Vaccine 24(Suppl 3):1-10.
24. Paavonen J, et al. 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301-314.
25. Sangwa-Lugoma G, et al. 2006. Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. Int. J. Cancer 119:1389-1395. (Pubitemid 44258816)
26. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. 2007. Human papillomavirus and cervical cancer. Lancet 370:890-907. (Pubitemid 47371147)
27. Schiffman M, et al. 2011. Human papillomavirus testing in the prevention of cervical cancer. J. Natl. Cancer Inst. 103:368-383.
28. Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL. 2011. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev. Med. 53(Suppl 1):S12-S21.
29. van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B. 2006. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J. Clin. Microbiol. 44:3292-3298. (Pubitemid 44413767)
30. Wolfgramm Ede V, et al. 2009. Simplified buccal DNA extraction with FTA elute cards. Forensic Sci. Int. Genet. 3:125-127.
31. World Health Organization. 2012. Guidance on regulations for the transport of infectious substances 2011-2012. International Health Regulations Coordination, World Health Organization, Geneva, Switzerland. http: //www.who.int/ihr/publications/who-hse-ihr-20100801-en.pdf.